A phase 2, randomized, placebo-controlled, double-blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb C->t mutation to evaluate the safety, tolerability, phamacokinetics and preliminary efficacy of SLP84
Obert
- Codi protocol: SPL84-002
- Codi EudraCT: No aplica
- Grup de recerca: Pneumologia
- Servei: Pneumologia
- Investigador/a principal: Álvarez Fernandez, Antonio
- Malaltia: Malalties del sistema respiratori
- Fase: Fase II
- Estat: Reclutant voluntaris